Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Six Tips on How to Spot a Winning Biotech, From Dendreon Co-Founder Chris Henney
|
Luke Timmerman |
10/14/09 |
Seattle
|
|
Dendreon May Not Survive Its Success: Q&A with Founder Chris Henney, Part 1
|
Luke Timmerman |
07/27/09 |
Seattle
|
|
Biogen Gets Int’l Rights to Acorda’s MS Drug
|
Roxanne Palmer |
07/01/09 |
Boston
|
|
Biogen Reports 10th PML Case in Tysabri Patient
|
Roxanne Palmer |
06/29/09 |
Boston
|
|
EMD Serono Staging Battle Against Multiple Sclerosis in Boston, Chief Says
|
Ryan McBride |
06/08/09 |
Boston
|
|
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter
|
Luke Timmerman |
11/25/08 |
Boston
|
|
Alnylam–Isis Venture Regulus, Leader in MicroRNA Drugs, Aspires to Create New Paradigm of Treatments
|
Luke Timmerman |
10/24/08 |
San Diego
|
|
Seeding Labs Kickstarts Science in Developing Countries
|
Erik Mellgren |
06/24/08 |
Boston
|
|
Genzyme Seeks Dual Approval, Google Health Picks Another Massachusetts Partner, Biogen Shareholders To Provide Closure (Maybe), & More Life Science News
|
Rebecca Zacks |
06/19/08 |
Boston
|
|
Biogen Directors Win Backing From Third Advisory Firm, Icahn Could Be Heading For Defeat
|
Luke Timmerman |
06/12/08 |
Boston
|
|
Biogen Idec’s Nominees Win Support from Shareholder Advisory Firms
|
Luke Timmerman |
06/10/08 |
Boston
|
|
Icahn Turns Up Heat, Files Suit to Force Biogen Idec to Turn Over Records of Failed Sale
|
Robert Buderi |
04/09/08 |
Boston
|
|
Exact Sciences Puts Itself on the Block After Investor’s Prodding
|
Rebecca Zacks |
03/18/08 |
Boston
|
|
Biogen Bouncing Back From Tysabri Warning News
|
Rebecca Zacks |
02/28/08 |
Boston
|
|
With a Whole Lot of Spending to Do, Vertex Seeks Some $400 Million in Stock and Note Offerings
|
Rebecca Zacks |
02/13/08 |
Boston
|
|
Biogen Idec: Earnings Up, Gauntlet Down, Headhunters All Around?
|
Rebecca Zacks |
02/07/08 |
Boston
|
|
ImmunoGen Scores $1.5M From Biogen Idec
|
Rebecca Zacks |
02/04/08 |
Boston
|
|
Icahn to Nominate Three, Including Two Harvard Bigwigs, to Biogen Idec Board
|
Rebecca Zacks |
01/28/08 |
Boston
|
|
Icahn: Biogen Idec Will Be Bought
|
Robert Buderi |
01/16/08 |
Boston
|
|
Biogen Idec’s Tysabri Approved for Crohn’s
|
Rebecca Zacks |
01/14/08 |
Boston
|
|
Biogen Idec, Vertex, and Genzyme Try Different Ways to Skin the Innovation Cat
|
Rebecca Zacks |
12/19/07 |
Boston
|
|
Biogen Inks $380 Million Deal With Swiss Company
|
Rebecca Zacks |
11/20/07 |
Boston
|
|
Bidding for Biogen Idec Could Begin in Early November, Report Says
|
Robert Buderi |
10/26/07 |
Boston
|
|
Biogen-Icahn? Pfiz-ogen or Pfiz-zyme? Is All of Cambridge Biotech Suddenly Up For Sale?
|
Robert Buderi |
10/24/07 |
Boston
|
|
Icahn Offered $23 Billion for Biogen Idec—Elan Won’t Block Sale
|
Robert Buderi |
10/15/07 |
Boston
|
|
Biogen Idec on the Block; Icahn’s Interest in Buying the Firm Confirmed
|
Rebecca Zacks |
10/12/07 |
Boston
|
|
Carl Icahn: Biogen Idec Marriage Broker?
|
Robert Buderi |
08/27/07 |
Boston
|
|
Icahn Gets Okay to Purchase Biogen Idec Shares
|
Robert Buderi |
08/25/07 |
Boston
|
|
Color Kinetics Sale on Track, Boston Scientific and Amgen Retrench, & More
|
Rebecca Zacks |
08/17/07 |
Boston
|
|
Keeping Biogen Idec Innovative: Jim Mullen Interview (Part 2)
|
Robert Buderi |
08/17/07 |
Boston
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
